Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
Saved in:
| Title: | Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. |
|---|---|
| Authors: | Petersenn S; ENDOC Center for Endocrine Tumors, Hamburg, Germany. stephan.petersenn@endoc-med.de., Salgado LR; Division of General Internal Medicine, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil., Schopohl J; Medizinische Klinik IV, University of Munich, Munich, Germany., Portocarrero-Ortiz L; Department of Neuroendocrinology, National Institute of Neurology and Neurosurgery, Mexico City, Mexico., Arnaldi G; Division of Endocrinology, Polytechnic University of Marche Region, Ancona, Italy., Lacroix A; Division of Endocrinology, Centre hospitalier de l'Université de Montréal, Montreal, Canada., Scaroni C; Endocrinology Unit, Department of Medicine, Padova University Hospital, Padova, Italy., Ravichandran S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Kandra A; Novartis Pharma AG, Basel, Switzerland., Biller BMK; Neuroendocrine Clinical Center, Massachusetts General Hospital, Boston, MA, USA. |
| Source: | Endocrine [Endocrine] 2017 Jul; Vol. 57 (1), pp. 156-165. Date of Electronic Publication: 2017 Jun 09. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 9434444 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0100 (Electronic) Linking ISSN: 1355008X NLM ISO Abbreviation: Endocrine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
